Abstracts Archive - Page 1495 of 2607 - ACR Meeting Abstracts

Abstract Number: 1616 • 2017 ACR/ARHP Annual Meeting
Early and Late Onset Biopsy Proven Lupus Nephritis without Other Associated Autoimmune Diseases: Severity and Long-Term Outcome
Michelle Lopes¹, Laryssa Santos², Luciana Seguro³ and Eloisa Bonfa⁴, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Lupus nephritis (LN) usually develops within the first years of Systemic Lupus Erythematosus (SLE) onset and rarely after that. There are scarce studies comparing…
Abstract Number: 1617 • 2017 ACR/ARHP Annual Meeting
Autoimmune Diseases in Patients with Cutaneous Lupus Erythematosus
Elaine Kunzler^1,2, Linda S. Hynan³ and Benjamin F. Chong¹, ¹Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ²Northeast Ohio Medical University, Rootstown, OH, ³Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Increased rates of co-existing autoimmune diseases in the systemic lupus erythematosus (SLE) population have been reported.1 Little is known about the prevalence of autoimmune…
Abstract Number: 1618 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Development of Early Infectious and Non-Infectious Complications in Systemic Lupus Erythematosus Patients Undergoing Major Surgery
Lauro Quintanilla-González¹, Gonzalo Torres-Villalobos² and Andrea Hinojosa-Azaola³, ¹Immunology & Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Departmen of Experimental Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease with increased cardiovascular and infectious complications due to subclinical atherosclerosis, disease activity and treatment-related factors. The…
Abstract Number: 1619 • 2017 ACR/ARHP Annual Meeting
The Impact of Disease Characteristics on Habitual Physical Activity and Sedentary Behavior Among Patients with Systemic Lupus Erythematosus (SLE)
Alexandra Legge¹, Chris Blanchard¹ and John G. Hanly², ¹Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ²Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for atherosclerotic cardiovascular disease (ASCVD). As sedentary behavior and lack of physical activity are…
Abstract Number: 1620 • 2017 ACR/ARHP Annual Meeting
Habitual Physical Activity, Sedentary Behavior and Cardiovascular Disease Risk Burden in Systemic Lupus Erythematosus (SLE)
Alexandra Legge¹, Chris Blanchard¹ and John G. Hanly², ¹Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ²Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Patients with SLE are at increased risk for atherosclerotic cardiovascular disease (ASCVD). As sedentary behavior and lack of physical activity (PA) have been identified…
Abstract Number: 1621 • 2017 ACR/ARHP Annual Meeting
Prevalence of Cognitive Impairment in Systemic Lupus Erythematosus Assessed By the Automated Neuropsychological Assessment Metrics
Zahi Touma¹, Robin Green², Lesley Ruttan³, Sabrina Lombardi³, Carmela Tartaglia⁴, Nicole Anderson⁵, Jiandong Su⁶, Kenneth Colosimo⁶, Michelle Vitti⁶, Dennisse Bonilla⁶, Joan E. Wither⁵, Marvin J. Fritzler⁷ and Dorcas Beaton⁸, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Brain and Therapeutics, Toronto Rehabilitation Institute, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁴University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Medicine, University of Calgary, Calgary, AB, Canada, ⁸Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada
Background/Purpose: The screening and diagnosis of Cognitive Impairment (CI) in Systemic Lupus Erythematosus (SLE) patients is often delayed. CI diagnosed according to the American College…
Abstract Number: 1622 • 2017 ACR/ARHP Annual Meeting
Associations Among Classification Criteria Items within Systemic Lupus Erythematosus
Zahi Touma¹, Ricard Cervera², Ralph Brinks³, Chiara Tani⁴, Bimba F. Hoyer⁵, Karen H. Costenbader⁶, Valentina Lorenzoni⁷, Gian Sebastiani⁸, Sandra V. Navarra⁹, Eloisa Bonfa¹⁰, Rosalind Ramsey-Goldman¹¹, Sara K. Tedeschi¹², Thomas Doerner¹³, Sindhu Johnson¹⁴, Martin Aringer¹⁵ and Marta Mosca¹⁶, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, ³Hiller Center for Research in Rheumatology, Dusseldorf, Germany, ⁴University of Pisa, Pisa, Italy, ⁵Charité University Medicine, Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Sant Anna Scuola Universitaria Superiore Pisa, Pisa, Italy, ⁸Ospedale San Camillo, Rome, Italy, ⁹Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ¹⁰Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ¹¹FSM, Northwestern University, Chicago, IL, ¹²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹³Charité Universitätmedizin Berlin and DRFZ, Berlin, Germany, ¹⁴Division of Rheumatology, University of Toronto, Toronto Scleroderma Program, Sinai Health Systems and University Health Network, Toronto, ON, Canada, ¹⁵Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, ¹⁶Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: An EULAR/ACR –sponsored project is currently developing new weighted SLE classification criteria including laboratory/clinical items. Combinations of symptoms appear commonly in SLE arguing against…
Abstract Number: 1623 • 2017 ACR/ARHP Annual Meeting
Prevalence of Cognitive Impairment in Systemic Lupus Erythematosus Assessed By a Comprehensive Neuropsychological Battery
Zahi Touma¹, Robin Green², Carmela Tartaglia³, Lesley Ruttan⁴, Sabrina Lombardi⁴, Nicole Anderson⁵, Jiandong Su⁶, Kenneth Colosimo⁶, Michelle Vitti⁶, Dennisse Bonilla⁶, Joan E. Wither⁵, Marvin J. Fritzler⁷ and Dorcas Beaton⁸, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Brain and Therapeutics, Toronto Rehabilitation Institute, Toronto, ON, Canada, ³University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁴Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Medicine, University of Calgary, Calgary, AB, Canada, ⁸Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is a common neurobehavioural manifestation of SLE. In our recent systematic review, the prevalence of CI was 38% (95% CI: 33-43%)…
Abstract Number: 1624 • 2017 ACR/ARHP Annual Meeting
SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG) Identifies More Responders Than Sledai-2K
Zahi Touma¹, Dafna D Gladman², Jiandong Su³, Nicole Anderson⁴ and Murray Urowitz⁴, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) is one of the most commonly used disease activity indices in clinical practice and research but this…
Abstract Number: 1625 • 2017 ACR/ARHP Annual Meeting
Incidence and Outcomes of Venous Thromboembolism in Hospitalized Patients with Systemic Lupus Erythematosus: Results from Nationwide Inpatient Sample Database 2003-2011
Shweta Kishore¹, Varun Mittal², Shradha Ahuja³ and Vikas Majithia^1,4, ¹Division of Rheumatology, University of Mississippi, Jackson, MS, ²Division of Hematology and Oncology, Albert Einstein Healthcare Network, Philadelphia, PA, ³Division of Hospital Medicine, University of Mississippi, Jackson, MS, ⁴Jackson VA Medical Center and University of Mississippi, Jackson, MS
Background/Purpose: Venous thromboembolism (VTE) is a major cause of mortality and morbidity in hospitalized patients. Hospitalized patients with autoimmune disorders are particularly at risk of…
Abstract Number: 1626 • 2017 ACR/ARHP Annual Meeting
Childhood-Onset Predicts Increased Steroid-Related Damage Among Adults with Systemic Lupus Erythematosus
Merav Heshin-Bekenstein¹, Emily von Scheven², Aimee O. Hersh³, Laura Trupin⁴, Edward H. Yelin⁴ and Erica Lawson¹, ¹Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, ²Division of Rheumatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Childhood-onset SLE (cSLE) often presents with severe disease, managed with high-dose steroids. However, little is known about differences in long-term steroid toxicity between adults…
Abstract Number: 1627 • 2017 ACR/ARHP Annual Meeting
Changes in Heart Rate Variability Reflect Changes in Clinical Status and Patient Reported Outcomes in Systemic Lupus Erythematosus: A Longitudinal Analysis
Aikaterini Thanou¹, Stavros Stavrakis², Justin Reynolds³, Stan Kamp¹, Paul Kamp¹, Judith A. James⁴ and Joan T. Merrill⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Ok, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: We have previously observed associations between systemic lupus erythematosus (SLE) disease activity and heart rate variability (HRV) between 2 time points (1). We aim…
Abstract Number: 1628 • 2017 ACR/ARHP Annual Meeting
Atrial Fibrillation/Flutter Hospitalizations Among Patients with SLE and Diabetes Compared to the General U.S. Medicaid Population
Sarah Chen¹, Medha Barbhaiya², Michael A. Fischer³, Hongshu Guan⁴, Candace H. Feldman⁵, Brendan M. Everett⁶ and Karen H. Costenbader⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁶Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: SLE patients have increased cardiovascular disease (CVD) risk, including higher risk of stroke, compared to age- and sex-matched diabetes mellitus (DM) patients. Although DM…
Abstract Number: 1629 • 2017 ACR/ARHP Annual Meeting
Disease Activity Is an Independent Predictor of Leukopenia in a Large International SLE Cohort
Rangi Kandane-Rathnayake¹, Vera Golder², Worawit Louthrenoo³, Sargunan Sockalingam⁴, Aisha Lateef⁵, Yuan An⁶, Leonid Zamora⁷, Yeong-Jian Wu⁸, Shue-Fen Luo⁹, Madelynn Chan¹⁰, Fiona Goldblatt¹¹, Chak Sing Lau¹², Zhan-Guo Li¹³, Sandra V. Navarra⁷, Mandana Nikpour¹⁴, Eric F Morand¹⁵ and Alberta Y. Hoi², ¹Rheumatology, Monash University, Melbourne, Australia, ²Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ³Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁴University of Malaya, Kuala Lumpur, Malaysia, ⁵Medicine, Division of Rheumatology, National University Hospital of Singapore, Singapore, Singapore, ⁶Peking University People's Hospital, Beijing, China, ⁷Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ⁸Chang Gung University, Taoyuan County, Taiwan, ⁹Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ¹⁰Tan Tock Seng Hospital, Singapore, Singapore, ¹¹Flinders University, Adelaide, Australia, ¹²Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ¹³Peking University International Hospital, Beijing, China, ¹⁴Melbourne University, Melbourne, Australia, ¹⁵Monash University, Melbourne, Australia
Background/Purpose: Leukopenia is commonly seen in SLE, but its predictors are not well understood, as it can be a result of disease activity or bone…
Abstract Number: 1630 • 2017 ACR/ARHP Annual Meeting
Achievement of Lupus Low Disease Activity State (LLDAS) in the Early Phase of Systemic Lupus Erythematosus Prevent Damage Accrual
Matteo Piga, Alberto Floris, Giulia Cappellazzo, Alessandro Mathieu and Alberto Cauli, Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy
Background/Purpose: The Asia-Pacific Collaboration Group has recently proposed the definition of Lupus Low Disease Activity state (LLDAS). This potential target in SLE treatment has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].